Glendon E. French III - Apr 15, 2021 Form 4/A - Amendment Insider Report for Pulmonx Corp (LUNG)

Role: President and CEO, Director
Signature: /s/ Lauren Cristina, Attorney-in-Fact for Glendon E. French
Stock symbol: LUNG
Transactions as of: Apr 15, 2021
Transactions value $: -$1,038,856
Form type: 4/A - Amendment
Date filed: 12/3/2021, 05:46 PM
Date Of Original Report: Apr 16, 2021
Next filing: Dec 3, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LUNG	Common Stock	Options Exercise	$55K	+25K	+2%	$2.20^*	1.27M	Apr 15, 2021	Direct
transaction	LUNG	Common Stock	Sale	-$872K	-20K	-1.57%	$43.64	1.25M	Apr 15, 2021	Direct	F1, F2
transaction	LUNG	Common Stock	Sale	-$222K	-5.01K	-0.4%	$44.21	1.25M	Apr 15, 2021	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LUNG	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-11.9%	$0.00	185K	Apr 15, 2021	Common Stock	25K	$2.20	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $44.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.13 to $44.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

This amendment is filed to correct the inadvertent omission of the option exercise transaction and the amount of securities beneficially owned following the reported transactions in columns 9 and 5 of each of the reported row in Table II and Table I, respectively. The error in columns 9 and 5 also appears in subsequent Forms 4 filed through November 22, 2021.